{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-005094","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.223707+00:00","generated_at":"2026-06-13T02:19:17.131722+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Phio shareholders approve incentive plan amendment, adding 125,500 shares","bullets":["At July 20, 2023 annual meeting, shareholders approved amendment to 2020 Long Term Incentive Plan.","Plan shares increased by 125,500 to a total of 225,500 shares available for issuance.","All five director nominees elected: Bitterman, Bradford, Ferrara, Freeman, Lockshin.","BDO USA LLP ratified as independent auditor for FY 2023 with 605,026 for, 21,903 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-005094","json":"https://secwatch.observer/filing/0001683168-23-005094.json","markdown":"https://secwatch.observer/filing/0001683168-23-005094.md","text":"https://secwatch.observer/filing/0001683168-23-005094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:19:17.131722+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f28c49eaf62cc4f2448a504410bd567cb10542f4","claim":"Phio Pharmaceuticals Corp. shareholders approved Ratification of BDO USA, LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-07-20 meeting.","evidence_excerpt":"Proposal 2: Ratification of Auditors For Against Abstain 605,026 21,903 3,171","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-07-20"}],"fact_type":"shareholder_vote"},{"claim_id":"f85f8936f0cd13926616aede45e770b6e07e77fd","claim":"Phio Pharmaceuticals Corp. shareholders approved Election of five directors to serve until the 2024 Annual Meeting at the 2023-07-20 meeting.","evidence_excerpt":"Nominee For Withheld Broker Non-Votes Robert J. Bitterman 126,094 17,995 486,011","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-07-20"}],"fact_type":"shareholder_vote"},{"claim_id":"fed5831d83aa671448866db7a4d20fa4765b8d4d","claim":"Phio Pharmaceuticals Corp. shareholders approved Amendment and restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan to increase the number of shares by 125,500 at the 2023-07-20 meeting.","evidence_excerpt":"Proposal 3: Amendment and Restatement of the 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan For Against Abstain Broker Non-Votes 98,254 44,696 1,139 486,011","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316823005094/0001683168-23-005094-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-07-20"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}